title: Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
authors: Neurology, University Hospital, Ostrava, Czech Republic.
authors: Pavel
authors: P
authors: Hradilek
authors: David
authors: D
authors: Zeman
authors: Ivan
authors: I
authors: Tudik
authors: Olga
authors: O
authors: Zapletalova
authors: Vit
authors: V
authors: Ulmann
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000995:Antitubercular Agents / Q000627:therapeutic use; D058070:Asymptomatic Diseases; D004334:Drug Administration Schedule; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D009165:Mycobacterium Infections, Nontuberculous / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D019909:Mycobacterium kansasii / Q000302:isolation & purification*; D000069442:Natalizumab; D009894:Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D000069442:Natalizumab